NCT06239389 - Comparison Of Efficacy And Safety Of Thalidomide Vs Hydroxyurea In Thalassemia Patients: A Single-Centre Pilot Study. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

March 3, 2022

Conditions

Beta-Thalassemia

Interventions

DRUG

Thalidomide 100mg

Thalidomide is available in capsulated form in the strength of 100 mg and 50 mg. It was given according to the weight of the patient. Due to somnolence, it was advised to give at night only.

DRUG

Hydroxyurea

Hydroxyurea is available in capsulated form under the brand of hydrea. Its available strength is 500 mg . Dosing depends upon weight of patient, that is 15mg/kg/day. so patients unable to take full capsule due to low weight, was advised to take hydroxyurea syrup.

Trial Locations (1)

75300

National Institute of Blood Diseases and Bone Marrow Transplantation, Karachi

All Listed Sponsors

lead

National Institute of Blood and Marrow Transplant (NIBMT), Pakistan

OTHER_GOV